Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 3/2011

01.03.2011 | Article

Diagnostic value of procalcitonin in pleural effusions

verfasst von: C.-Y. Wang, Y.-C. Hsiao, J.-S. Jerng, C.-C. Ho, C.-C. Lai, C.-J. Yu, P.-R. Hsueh, P.-C. Yang

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

This study was to determine the diagnostic value of procalcitonin (PCT) in the differentiation of infectious and non-infectious causes of pleural effusion. From January 2005 to April 2005, we measured the PCT levels of pleural effusion from 76 patients using an immunoluminometric assay. The types of pleural infusions studied were para-pneumonic effusion (n = 26), empyema (n = 7), tuberculous pleurisy (n = 8), malignant pleural effusion (n = 25) and transudative pleural effusion (n = 8). The PCT levels were low in transudative pleural effusions (0.188 ± 0.077 ng/mL) and tuberculous pleurisy (0.130 ± 0.069 ng/mL), but high in empyema (5.147 ± 3.056 ng/mL), para-pneumonic effusion (1.091 ± 0.355 ng/mL), and malignant pleural effusion (0.241 ± 0.071 ng/mL). The receiver-operating characteristic curve analysis for an optimal discrimination between empyema and para-pneumonic effusion from non-para-pneumonic effusion could be performed at a cut-off point of 0.18 ng/mL with area under the curve of 0.776 (sensitivity: 69.7%, specificity: 72.1%). The correlation was found between pleural effusion PCT and serum PCT levels in 16 patients (r 2 = 0.967, p < 0.001). In conclusion, a high pleural effusion PCT level suggests the presence of empyema and para-pneumonic effusion.
Literatur
1.
Zurück zum Zitat Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518CrossRefPubMed Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518CrossRefPubMed
2.
Zurück zum Zitat Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL (1999) Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 27:498–504CrossRefPubMed Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL (1999) Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 27:498–504CrossRefPubMed
3.
Zurück zum Zitat Meisner M, Tschaikowsky K, Palmaers T, Schmidt J (1999) Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 3:45–55CrossRefPubMed Meisner M, Tschaikowsky K, Palmaers T, Schmidt J (1999) Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 3:45–55CrossRefPubMed
4.
Zurück zum Zitat Luyt CE, Guerin V, Combes A et al (2005) Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 171:48–53CrossRefPubMed Luyt CE, Guerin V, Combes A et al (2005) Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 171:48–53CrossRefPubMed
5.
Zurück zum Zitat Brunkhorst FM, Eberhard OK, Brunkhorst R (1999) Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 27:2172–2176CrossRefPubMed Brunkhorst FM, Eberhard OK, Brunkhorst R (1999) Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 27:2172–2176CrossRefPubMed
6.
Zurück zum Zitat Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M et al (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. Lancet 363:600–607CrossRefPubMed Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M et al (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. Lancet 363:600–607CrossRefPubMed
7.
Zurück zum Zitat Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr (1972) Pleural effusion: the diagnostic separation of transudates and exudates. Ann Intern Med 77:507–513PubMed Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr (1972) Pleural effusion: the diagnostic separation of transudates and exudates. Ann Intern Med 77:507–513PubMed
8.
Zurück zum Zitat Porcel JM, Vives M, Cao G, Bielsa S, Ruiz-González A, Martínez-Iribarren A et al (2009) Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J 34:1383–1389CrossRefPubMed Porcel JM, Vives M, Cao G, Bielsa S, Ruiz-González A, Martínez-Iribarren A et al (2009) Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J 34:1383–1389CrossRefPubMed
9.
Zurück zum Zitat Lin MC, Chen YC, Wu JT, Ko YC, Wang CC (2009) Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest 136:205–211CrossRefPubMed Lin MC, Chen YC, Wu JT, Ko YC, Wang CC (2009) Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest 136:205–211CrossRefPubMed
10.
Zurück zum Zitat Baylan O, Balkan A, Inal A, Kisa O, Albay A, Doganci L et al (2006) The predictive value of serum procalcitonin levels in adult patients with active pulmonary tuberculosis. Jpn J Infect Dis 59:164–167PubMed Baylan O, Balkan A, Inal A, Kisa O, Albay A, Doganci L et al (2006) The predictive value of serum procalcitonin levels in adult patients with active pulmonary tuberculosis. Jpn J Infect Dis 59:164–167PubMed
11.
Zurück zum Zitat Nyamande K, Lalloo UG (2006) Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 10:510–515PubMed Nyamande K, Lalloo UG (2006) Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 10:510–515PubMed
12.
Zurück zum Zitat Schleicher GK, Herbert V, Brink A, Martin S, Maraj R, Galpin JS et al (2005) Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 25:688–692CrossRefPubMed Schleicher GK, Herbert V, Brink A, Martin S, Maraj R, Galpin JS et al (2005) Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 25:688–692CrossRefPubMed
13.
Zurück zum Zitat Cakir E, Deniz O, Ozcan O, Tozkoparan E, Yaman H, Akgul EO et al (2005) Pleural fluid and serum procalcitonin as diagnostic tools in tuberculous pleurisy. Clin Biochem 38:234–238CrossRefPubMed Cakir E, Deniz O, Ozcan O, Tozkoparan E, Yaman H, Akgul EO et al (2005) Pleural fluid and serum procalcitonin as diagnostic tools in tuberculous pleurisy. Clin Biochem 38:234–238CrossRefPubMed
14.
Zurück zum Zitat Ho CC, Liao WY, Wang CY, Lu YH, Huang HY, Chen HY et al (2008) TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 177:763–770CrossRefPubMed Ho CC, Liao WY, Wang CY, Lu YH, Huang HY, Chen HY et al (2008) TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 177:763–770CrossRefPubMed
15.
Zurück zum Zitat Topolcan O, Holubec L, Polivkova V, Svobodova S, Pesek M, Treska V et al (2007) Tumor markers in pleural effusions. Anticancer Res 27:1921–1924PubMed Topolcan O, Holubec L, Polivkova V, Svobodova S, Pesek M, Treska V et al (2007) Tumor markers in pleural effusions. Anticancer Res 27:1921–1924PubMed
16.
Zurück zum Zitat Chierakul N, Kanitsap A, Chaiprasert A, Viriyataveekul R (2004) A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion. Respirology 9:66–69CrossRefPubMed Chierakul N, Kanitsap A, Chaiprasert A, Viriyataveekul R (2004) A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion. Respirology 9:66–69CrossRefPubMed
17.
Zurück zum Zitat Garcia-Pachon E, Llorca I (2002) Diagnostic value of C-reactive protein in exudative pleural effusions. Eur J Intern Med 13:246–249CrossRefPubMed Garcia-Pachon E, Llorca I (2002) Diagnostic value of C-reactive protein in exudative pleural effusions. Eur J Intern Med 13:246–249CrossRefPubMed
18.
Zurück zum Zitat Chan MC, Chang KM, Chao WC, Lin LY, Kuo BI, Hsu JY et al (2007) Evaluation of a new inflammatory molecule (triggering receptor expressed on myeloid cells-1) in the diagnosis of pleural effusion. Respirology 12:333–338CrossRefPubMed Chan MC, Chang KM, Chao WC, Lin LY, Kuo BI, Hsu JY et al (2007) Evaluation of a new inflammatory molecule (triggering receptor expressed on myeloid cells-1) in the diagnosis of pleural effusion. Respirology 12:333–338CrossRefPubMed
19.
Zurück zum Zitat Liu CL, Hsieh WY, Wu CL, Kuo HT, Lu YT (2007) Triggering receptor expressed on myeloid cells-1 in pleural effusions: a marker of inflammatory disease. Respir Med 101:903–909CrossRefPubMed Liu CL, Hsieh WY, Wu CL, Kuo HT, Lu YT (2007) Triggering receptor expressed on myeloid cells-1 in pleural effusions: a marker of inflammatory disease. Respir Med 101:903–909CrossRefPubMed
20.
Zurück zum Zitat Becker KL, Nylén ES, White JC, Müller B, Snider RH Jr (2004) Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 89:1512–1525CrossRefPubMed Becker KL, Nylén ES, White JC, Müller B, Snider RH Jr (2004) Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 89:1512–1525CrossRefPubMed
21.
Zurück zum Zitat Leon ALC, Cousson J, Raclot P, Suinat JL, Assicot M, Bohuon C (1995) 5th Vienna Shock Forum. Vienna, Austria, May 7–11, 1995. Abstracts. Shock 3 [Suppl]:1–84 Leon ALC, Cousson J, Raclot P, Suinat JL, Assicot M, Bohuon C (1995) 5th Vienna Shock Forum. Vienna, Austria, May 7–11, 1995. Abstracts. Shock 3 [Suppl]:1–84
Metadaten
Titel
Diagnostic value of procalcitonin in pleural effusions
verfasst von
C.-Y. Wang
Y.-C. Hsiao
J.-S. Jerng
C.-C. Ho
C.-C. Lai
C.-J. Yu
P.-R. Hsueh
P.-C. Yang
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 3/2011
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-010-1082-0

Weitere Artikel der Ausgabe 3/2011

European Journal of Clinical Microbiology & Infectious Diseases 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.